Get the Stockscreener App
10.80
1.01%
-0.11
After Hours:
10.90
0.10
+0.93%
Kalvista Pharmaceuticals Inc stock is traded at $10.80, with a volume of 1.12M.
It is down -1.01% in the last 24 hours and down -8.86% over the past month.
KalVista Pharmaceuticals Inc is a pharmaceutical company developing and delivering oral therapies for individuals affected by rare diseases with unmet needs. The company applies its knowledge in the kallikrein-kinin system (KKS) and oral drug discovery to develop small-molecule protease inhibitor medicines to address the needs of patients with diseases driven by plasma kallikrein and Factor XIIa. Its FDA-approved product EKTERLY (sebetralstat) is a novel, orally delivered, small-molecule plasma kallikrein inhibitor for the treatment of acute attacks of hereditary angioedema (HAE) in adult and pediatric patients aged twelve years and older.
See More
Previous Close:
$10.91
Open:
$10.82
24h Volume:
1.12M
Relative Volume:
1.03
Market Cap:
$545.65M
Revenue:
-
Net Income/Loss:
$-156.39M
P/E Ratio:
-2.9268
EPS:
-3.69
Net Cash Flow:
$-123.06M
1W Performance:
-3.83%
1M Performance:
-8.86%
6M Performance:
-20.30%
1Y Performance:
+1.79%
1-Day Range:
$10.51
$11.16
1-Week Range:
$10.51
$11.42
52-Week Range:
$7.30
$17.28
Kalvista Pharmaceuticals Inc Stock (KALV) Company Profile
Name
Kalvista Pharmaceuticals Inc
Sector
Industry
Phone
(857) 999-0075
Address
200 CROSSING BOULEVARD, FRAMINGHAM, MA
Compare KALV with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
KALV
Kalvista Pharmaceuticals Inc
|
10.80 | 551.21M | 0 | -156.39M | -123.06M | -3.69 |
|
VRTX
Vertex Pharmaceuticals Inc
|
426.00 | 109.11B | 11.39B | 3.64B | 3.50B | 13.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
642.25 | 68.50B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
434.07 | 60.25B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
826.28 | 50.39B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
186.23 | 40.44B | 447.02M | -1.18B | -868.57M | -6.1812 |
Kalvista Pharmaceuticals Inc Stock (KALV) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jan-31-25 | Initiated | JMP Securities | Mkt Outperform |
| Jan-07-25 | Initiated | TD Cowen | Buy |
| Dec-18-24 | Initiated | BofA Securities | Buy |
| Jun-15-20 | Initiated | H.C. Wainwright | Buy |
| Jul-29-19 | Initiated | SVB Leerink | Outperform |
| Mar-20-19 | Initiated | Needham | Buy |
| Oct-30-18 | Initiated | Jefferies | Buy |
| Sep-21-18 | Initiated | Cantor Fitzgerald | Overweight |
| Aug-31-17 | Initiated | BTIG Research | Buy |
View All
Kalvista Pharmaceuticals Inc Stock (KALV) Latest News
Multi asset correlation models including KalVista Pharmaceuticals Inc.Portfolio Risk Summary & Weekly Breakout Watchlists - newser.com
Will KalVista Pharmaceuticals Inc. stock attract more institutional investors2025 Big Picture & Free Safe Capital Growth Stock Tips - newser.com
KalVista Pharmaceuticals to Host Third Quarter Financial Results Conference Call and Webcast on November 11, 2025 - The Joplin Globe
How to track smart money flows in KalVista Pharmaceuticals Inc.Quarterly Portfolio Review & Breakout Confirmation Trade Signals - newser.com
How KalVista Pharmaceuticals Inc. stock performs in high volatility marketsJuly 2025 Analyst Calls & Weekly Chart Analysis and Trade Guides - newser.com
Will KalVista Pharmaceuticals Inc. (4XC1) stock benefit from commodity supercycleJuly 2025 Snapshot & AI Powered Trade Plan Recommendations - newser.com
Why KalVista Pharmaceuticals Inc. (4XC1) stock is favored by hedge fundsQuarterly Growth Report & Weekly Top Performers Watchlists - newser.com
Using R and stats models for KalVista Pharmaceuticals Inc. forecastingJuly 2025 Pullbacks & Weekly Market Pulse Updates - newser.com
Can KalVista Pharmaceuticals Inc. (4XC1) stock sustain margin levelsQuarterly Earnings Summary & Reliable Price Breakout Signals - newser.com
Will KalVista Pharmaceuticals Inc. stock reach Wall Street targetsCPI Data & Weekly Breakout Watchlists - newser.com
What market sentiment indicators show for KalVista Pharmaceuticals Inc. (4XC1) stockProduct Launch & Fast Momentum Entry Tips - newser.com
How strong is KalVista Pharmaceuticals Inc. (4XC1) stock earnings growthJuly 2025 PostEarnings & Step-by-Step Swing Trade Plans - newser.com
What makes KalVista Pharmaceuticals Inc. stock attractive to growth funds2025 Price Momentum & Smart Money Movement Tracker - newser.com
Exit strategy if you’re trapped in KalVista Pharmaceuticals Inc.July 2025 Big Picture & Safe Entry Momentum Tips - newser.com
Will a bounce in KalVista Pharmaceuticals Inc. offer an exit2025 Support & Resistance & Daily Oversold Bounce Ideas - newser.com
How hedge fund analytics apply to KalVista Pharmaceuticals Inc. stockM&A Rumor & AI Driven Price Forecasts - newser.com
Is KalVista Pharmaceuticals Inc. (4XC1) stock a defensive play amid uncertaintyJuly 2025 Review & Technical Buy Zone Confirmation - newser.com
Will KalVista Pharmaceuticals Inc. (4XC1) stock keep high P E multiplesJuly 2025 Catalysts & Safe Entry Momentum Stock Tips - newser.com
KalVista, Ionis/Sobi among latest to win EU nod for rare disease drugs - MSN
Emerald Mutual Fund Advisers Trust Increases Stake in KalVista Pharmaceuticals, Inc. $KALV - MarketBeat
Emerald Advisers LLC Boosts Stock Position in KalVista Pharmaceuticals, Inc. $KALV - MarketBeat
KalVista Pharmaceuticals (NASDAQ:KALV) Shares Pass Below Fifty Day Moving AverageWhat's Next? - MarketBeat
KalVista Pharmaceuticals to Present New EKTERLY® (sebetralstat) Data at the American College of Allergy, Asthma & Immunology 2025 Annual Scientific Meeting - The Joplin Globe
Kalvista Pharmaceuticals Inc Stock (KALV) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.64%
0.35%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):